Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Neoplasms 2Small Cell Lung Carcinoma 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Small Cell 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms × GSK2879552 × Clear all
NCT02034123 2019-12-06

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

GlaxoSmithKline

Phase 1 Terminated
29 enrolled 34 charts
Thoracic

Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT02177812 2019-06-28

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

GlaxoSmithKline

Phase 1 Terminated
41 enrolled 34 charts
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡